In response to COVID-19, GHX is committed to helping ensure that our customers receive access to the data and information needed to help maintain critical supplies to serve patients and protect staff. Click to learn more
Log In

A recently published whitepaper on Rapid Innovation in Cardiovascular Technology: explores the clinical evidence in three cardiovascular devices

Before selecting any clinical treatment or modality, a comprehensive and also unbiased review and understanding of the clinical evidence is critical for the best patient outcomes. Three examples of innovative technology and the leading evidence are referenced in this whitepaper. 1. Transcatheter Aortic Valve Replacements (TAVR) is an effective therapy with evidence of product superiority; however patient characteristics are significant factors in product selection. 2. Arctic Front Advance is a promising technology and is currently considered an alternative, but not a superior treatment. 3. Absorb GT1 Bioresorbable Vascular Scaffold may not demonstrate superiority in clinical outcomes up to one year after implantation.

To read in full, you can access the whitepaper here

More News